article thumbnail

Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy

JAMA Cardiology

This randomized clinical trial assesses whether cardioverter-defibrillator implantation is more effective than amiodarone therapy for the primary prevention of all-cause mortality and secondary prevention of sudden cardiac death, hospitalization for heart failure, and use of a pacemaker among patients with chronic Chagas cardiomyopathy.

article thumbnail

Chronic Use of Amiodarone Against Implantable Cardioverter-Defibrillator Therapy for Primary Prevention of Death in Patients With Chagas Cardiomyopathy Study

American College of Cardiology

The goal of the CHAGASICS trial was to evaluate implantable cardioverter-defibrillators (ICDs) compared with amiodarone among patients with chronic Chagas cardiomyopathy.

article thumbnail

PO-02-167 FACTORS IMPACTING SHOCK IMPEDANCE IN SUBCUTANEOUS IMPLANTABLE-CARDIOVERTER DEFIBRILLATORS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

HeartRhythm

Hypertrophic cardiomyopathy (HCM) is associated with risk of sudden cardiac death (SCD). Since approval in late 2012, the subcutaneous implantable cardioverter-defibrillator (SICD) has been used as an alternative to the traditional transvenous ICD (TV-ICD) for SCD prevention in HCM.

article thumbnail

MP-470545-006 TEN-YEAR EXPERIENCE OF THE SUBCUTANEOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

HeartRhythm

Hypertrophic cardiomyopathy (HCM) is associated with risk of sudden cardiac death (SCD). Since approval in late 2012, the subcutaneous implantable cardioverter-defibrillator (SICD) has been used as an alternative to the traditional transvenous ICD (TV-ICD) for SCD prevention in HCM.

article thumbnail

PO-01-015 RATE OF APPROPRIATE AND INAPPROPRIATE THERAPY IN PATIENTS WITH NON-ISCHAEMIC CARDIOMYOPATHY – A COMPARISON BETWEEN PRIMARY AND SECONDARY PREVENTION IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR PATIENTS

HeartRhythm

Implantable cardioverter defibrillators (ICD) have proved their favourable outcomes on survival in selected patients with cardiomyopathy. However, recent studies have questioned the protective role of ICD in non-ischemic cardiomyopathy (NICM) for primary prevention.

article thumbnail

Intra-Pericardial Position of an Extra-Vascular Implantable Cardioverter-Defibrillator Lead

HeartRhythm

An 18-year-old male with arrhythmogenic cardiomyopathy was referred for catheter ablation of ventricular tachycardia after experiencing appropriate implantable cardioverter-defibrillator (ICD) shock. Six months prior, he had undergone uncomplicated implantation of an extravascular ICD (EV-ICD) [1].

article thumbnail

Efficacy of Catheter Ablation for Ventricular Tachycardia in Ischemic Cardiomyopathy Patients without an ICD Implantation

HeartRhythm

Implantable cardioverter defibrillator (ICD) prevents sudden cardiac death (SCD) in patients with ischemic cardiomyopathy (ICM). Catheter ablation has been shown to effectively reduce ventricular tachycardia (VT) recurrence, yet its efficacy in patients without an ICD implantation remains uncertain.